- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Review, Journal: Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. (Pubmed Central) - Dec 3, 2020 This trend has changed over the last 2 years with several compounds, such as lenvatinib (in first-line) and regorafenib, cabozantinib, ramucirumab and nivolumab (in second-line), showing clinical benefit...Conversely, PFS with a HR between 0.6-0.7, despite significant, was not associated with better survival, and thus these magnitudes are considered uncertain surrogates. In the current review, we discuss the reasons for positive or negative phase III trials in advanced HCC, and the strengths and limitations of clinical surrogate endpoints (PFS, TTP and objective response rate [ORR]) to predict survival.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors (clinicaltrials.gov) - Nov 24, 2020 P2, N=50, Recruiting, NLR can supportively be used as a tumor marker of RR-DTC and an indicator for starting lenvatinib treatment. Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, PD(L)-1 Biomarker, Metastases: Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 23, 2020 P2, N=76, Recruiting, Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Apr 2020 --> Apr 2021 Initiation date: Oct 2020 --> Jul 2020
- |||||||||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. (Pubmed Central) - Nov 21, 2020 Multiple clinical trials of combination immunotherapy have been recently completed, but interpretation of the results is hampered by small samples sizes and discordant outcomes. This review summarizes recent data on emerging treatments for neuroendocrine neoplasms.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, MSi-H Biomarker, PD(L)-1 Biomarker, IO Biomarker: A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. (Pubmed Central) - Nov 21, 2020 Based on substantial activity in a phase Ib/II study, the U.S. Food and Drug Administration (FDA) granted lenvatinib and pembrolizumab combination therapy accelerated approval in 2019 for the treatment of advanced endometrial cancer that is not MSI-H or dMMR and has progressed following prior therapy. Although these developments have been highly impactful, a more robust understanding of the molecular and immunologic drivers of response and resistance will be critical to optimally design next-generation studies in endometrial cancer.
- |||||||||| Stivarga (regorafenib) / Bayer, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. (Pubmed Central) - Nov 19, 2020 Similar adverse events were experienced by patients during consecutive treatment with sorafenib and regorafenib, which was not observed during treatment with sorafenib and lenvatinib. The obtained safety profile of sorafenib provided meaningful insights for selecting sequential therapy for patients with patients with advanced HCC.
|